USPTO 2015–2025 USPTO PatentsView US Corporation

Xyphos Biosciences Inc.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company

The verdict

According to USPTO PatentsView, Xyphos ranks #44,175 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#44,175
of 49,997 US assignees by volume
45th percentile
by Innovation Score (33.5/100)
10.7
avg claims per patent
+400%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R44175 · US Corporation #44,175 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 6 grants
  • LOWER-Q #44,175/49,997
  • PHOTO-FINISH Xact Laboratories
  • CPC-NARROW C07K · 4 areas
  • INNOV-THIN 33.5/100
  • CLAIMS-PAR 10.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +400% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Xact Laboratories, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Xyphos’s 33.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Xyphos

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Xyphos's Innovation Score is 33.5/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Xyphos?

Each dot is one of Xyphos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xyphos’s own 10.7 claims/patent is at or below the 13.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Xyphos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 5.96.06.066.06.06.1 5101520 Granted patents (volume) Avg claims / patent Xtralis Global - 6, 13.83Xtralis GlobalXuanzhu Biopharmaceutical Co., Ltd. - 6, 12.17Xuanzhu Biopharma…Xuzhou Zhirun Mining Equipment Science AND Technology Co., Ltd - 6, 8.33Xuzhou Zhirun Min…Xvivo Perfusion AB - 6, 17.17Xvivo Perfusion ABXYZ Energy Group, LLC - 6, 14.83XYZ Energy GroupXYZ Interactive Technologies Inc. - 6, 18.67XYZ InteractiveXact Laboratories, LLC - 6, 12.17Xact LaboratoriesXactiv, Inc. - 6, 14.67XactivXyphos Biosciences Inc. - 6, 10.67Xyphos Biosciences
Xyphos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Xyphos's grants concentrate

Xyphos Biosciences Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2019. By volume, Xyphos sits between Xtralis Global and Xactiv, Inc..

Xyphos's three-year grant acceleration

Xyphos Biosciences Inc. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Xyphos's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Xyphos holds 6 patents at rank #44,127, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Xyphos

By rank, the assignees closest to #44,127 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Xyphos's primary technology class.

Xyphos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 45th percentile higher than 45% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2019202120222024 2
USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Xyphos Biosciences Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 1 16.7%
2021 1 16.7%
2022 2 33.3%
2024 2 33.3%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Xyphos Biosciences Inc.'s patent record in context - here's where to go next.

  • Xyphos Biosciences Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #44,175 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Xyphos Biosciences Inc. against Xtralis Global, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.